{"id":"NCT02329860","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","briefTitle":"Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)","officialTitle":"A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study (AHELP) of Apatinib in Patients With Hepatocellular Carcinoma After Systemic Therapy（Chemotherapy and/or Targeted Therapy）","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-26","primaryCompletion":"2017-12-15","completion":"2019-08-14","firstPosted":"2015-01-01","resultsPosted":"2024-01-22","lastUpdate":"2024-01-22"},"enrollment":400,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Hepatocellular"],"interventions":[{"type":"DRUG","name":"Apatinib","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Apatinib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This was a multicenter, randomized, double-blind, phase III trial. This clinical study evaluates the efficacy and safety of Apatinib in patients with advanced liver cancer who have progressed on Systemic Therapy (Chemotherapy and/or Targeted Therapy).\n\nApproximately 400 patients who meet the entry criteria will be randomly assigned in a 2:1 ratio to Apatinib or placebo (1/3 chance to receive placebo).\n\nPrimary endpoint of the study is overall survival.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"Approximately 36 months","effectByArm":[{"arm":"Apatinib","deltaMin":8.7,"sd":null},{"arm":"Placebo","deltaMin":6.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["33971141"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":95,"n":257},"commonTop":["Aspartate aminotransferase increased","Blood bilirubin increased","Platelet count decreased","Palmar-plantar erythrodysaesthesia syndrome","Hypertension"]}}